Cangene (FRA:YGE) Other Gross PPE : €0.00 Mil (As of Oct. 2013)

View and export this data going back to . Start your Free Trial

What is Cangene Other Gross PPE?

Cangene's Other Gross PPE for the quarter that ended in Oct. 2013 was €0.00 Mil.

Cangene's quarterly Other Gross PPE declined from Apr. 2013 (€44.54 Mil) to Jul. 2013 (€3.30 Mil) and declined from Jul. 2013 (€3.30 Mil) to Oct. 2013 (€0.00 Mil).

Cangene's annual Other Gross PPE increased from Jul. 2011 (€0.35 Mil) to Jul. 2012 (€3.46 Mil) but then declined from Jul. 2012 (€3.46 Mil) to Jul. 2013 (€3.30 Mil).

Cangene Other Gross PPE Historical Data

The historical data trend for Cangene's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cangene Other Gross PPE Chart

Cangene Annual Data

Trend

Jul04

Jul05

Jul06

Jul07

Jul08

Jul09

Jul10

Jul11

Jul12

Jul13

Other Gross PPE

Get a 7-Day Free Trial

2.59

2.16

0.35

3.46

3.30

Cangene Quarterly Data
	Jan09	Apr09	Jul09	Oct09	Jan10	Apr10	Jul10	Oct10	Jan11	Apr11	Jul11	Oct11	Jan12	Apr12	Jul12	Oct12	Jan13	Apr13	Jul13	Oct13
Other Gross PPE	Get a 7-Day Free Trial															46.29	44.74	44.54	3.30	-

Cangene Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Cangene (FRA:YGE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cangene Corporation (FRA:YGE) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cangene.com

Cangene Corporation is a fully integrated developer and manufacturer of immune therapeutics, primarily targeting infectious disease, hematology, transplantation and biodefense applications. The company manages its business and evaluate performance based on two operating segments: biopharmaceutical operations and contract services. Revenues are generated from product sales, and contract manufacturing and contract-R&D services.

Cangene (FRA:YGE) Headlines

No Headlines